The pursuit of optimum outcomes in stable angina

American Journal of Cardiovascular Drugs

Volumn 3, Issue SUPPL. 1, 2003, Pages 11-20

  Thadani, Udho ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A ACYLTRANSFERASE; ACETYLSALICYLIC ACID; ANTIANGINA PECTORIS AGENT; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; ENZYME INHIBITOR; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC ACID DERIVATIVE; RANOLAZINE; TRIMETAZIDINE; VERAPAMIL;

ATHEROMA; ATHEROSCLEROSIS; BRADYCARDIA; BRONCHOSPASM; CONSTIPATION; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY THROMBOSIS; DAILY LIFE ACTIVITY; DEPRESSION; DRUG SAFETY; DRUG USE; DYSPNEA; EXERCISE TOLERANCE; FATTY ACID OXIDATION; FLUSHING; GROWTH RATE; HEADACHE; HEART BLOCK; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HEART PALPITATION; HEART VENTRICLE FUNCTION; HUMAN; HYPOTENSION; IMPOTENCE; INCIDENCE; LETHARGY; MORTALITY; PERIPHERAL EDEMA; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; SMOKING CESSATION; ST SEGMENT ELEVATION; STABLE ANGINA PECTORIS; SUDDEN DEATH; SYMPTOMATOLOGY; SYNCOPE; THROMBOCYTE AGGREGATION; THROMBOGENESIS; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; UNITED STATES; VASCULAR ENDOTHELIUM; VERTIGO; VIVID DREAM; WALKING;

EID: 0037250256     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200303001-00002     Document Type: Review

References (80)

1. Braunwald E, Sobel B. Coronary blood flow and myocardial ischemia. In: Braunwal E, editor. Heart disease: a textbook of cardiovascular medicine. Philadelphia: WB Sanders, 1988: 1191-1221
2. Thadani U. Medical therapy of stable angina pectoris. Cardiol Clin 1991; 9 (1): 73-88
3. Thadani U, Olson EG, Hamilton SF. Pathophysiology of myocardial ischemia in medical therapy of ischemic heart disease. In: Abrams J, Pepine CJ, Thadani U, editors. Medical therapy of ischemic heart disease: nitrates, beta-blockers and calcium antagonists. Boston: Little, Brown, 1992: 1-36
4. Davies MJ, Thomas AC. Plaque fissuring: the cause of acute myocardial infarction, sudden ischemic death, and crescendo angina. Br Heart J 1985; 53: 363-8
5. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115-26
6. Thadam U. Treatment of stable angina. Curr Opin Cardiol 1999; 14: 349-58
7. Thadani U. Stable angina pectoris. In: Crawford MH, Dimarco JP, editors. Cardiology. London, England: Mosby International Limited, 2001: 6.1-6.14
8. Asirvatham S. Sebastian C, Thadani U. Choosing the most appropriate treatment for stable angina: safety considerations. Drug Saf 1998; 19: 23-44
9. Gage JE, Jess DM, Murakami T, et al. Vasoconstriction of stenotic coronary arteries during dynamic exercise in patients with classic angina pectoris: reversibility by nitroglycerin. Circulation 1986; 73: 865-71
10. Sarnoff SJ, Braunwald E, Welch GH, et al. Hemodynamic determinants of oxygen consumption of the heart with special reference to the tension-time index. Am J Physiol 1958; 132: 148-56
11. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994; 344: 563-70
12. Peduzzi P, Kamina A, Detre K. Twenty-two-year follow-up in the VA cooperative study of Coronary Artery Bypass Surgery for Stable Angina. Am J Cardiol 1998; 81: 1393-9
13. Hartigan PM, Giacomini JC, Folland E, et al. Two- to three-year follow-up of patients with single-vessel coronary artery disease randomized to PTCA or medical therapy (results of a VA cooperative study). Veterans Affairs Cooperative Studies Program ACME Investigators. Angioplasty Compared to Medicine. Am J Cardiol 1998; 82: 1445-50
14. Thadani U, Chohan A. Chronic stable angina pectoris: strategies for effective drug therapy. Postgrad Med 1995; 98 (6): 175-88
15. Task Force of the European Society Cardiology. Management of stable angina pectoris: recommendations of the Task Force of the European Society Cardiology. Eur Heart J 1997; 18: 394-413
16. Canadian Cardiovascular Society 1997 Consensus Conference on the Evaluation and Management of Chronic Ischemic Heart Disease. Can J Cardiol 1998; 14 Suppl. C: 1C-23C
17. Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Chronic Stable Angina). Circulation 1999; 99: 2829-48
18. Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis of trials comparing β-blockers, calcium antagonists, and nitrates for stable angina. JAMA 1999; 281: 1927-36
19. Thadani U. Assessment of "optimal" beta-blockade in treating patients with angina pectoris. Acta Med Scand Suppl 1985; 694: 179-87
20. Thadani U. Management of patients with chronic stable angina at low risk for serious cardiac events. Am J Cardiol 1997; 79 (12B): 24-30
21. Davis R, Goldberg A, Forman S, et al. Asymptomatic cardiac ischemia pilot (ACIP) study two year follow up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization. Circulation 1997; 95 (8): 2037-43
22. Thadani U, Opie LH. Nitrates. In: Opie LH, editor. Drugs for the heart. 4th edn. Philadelphia: WB Saunders, 1995: 31-48
23. Thadani U. Nitrate tolerance, rebound and their clinical relevance in stable angina pectoris, unstable angina and heart failure. Cardiovasc Drugs Ther 1996; 10: 735-42
24. Opie LH, Frishman WH, Thadani U. Calcium channel antagonists (calcium entry blockers). In: Opie LT, editor. Drugs for the heart, 4th edn. Philadelphia: WB Saunders, 1995: 50-82
25. Thadani U. Selective L-type, T-type, and non specific calcium channel blockers for stable angina pectoris [editorial]. Am Heart J 2002; 1444: 8-10
26. Dargie HJ, Ford I, Fox KM. Total Ischaemic Burden European Trial (TIBET). Effects of ischemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group. Eur Heart J 1996; 17: 104-12
27. Thadani U. Combination therapy. ACC current journal review 1997; 6: 24-5
28. Dunselman P, van Kempen L, Bouwens L, et al. Value of the addition of amlodipine to atenolol in patients with angina pectoris despite adequate beta blockade. Am J Cardiol 1998; 81: 128-32
29. Knight C, Fox K. Amlodipine versus diltiazem as additional antianginal treatment to atenolol. Am J Cardiol 1998; 81: 133-6
30. Frishman W, Glasser S, Stone P, et al. Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. Am J Cardiol 1999; 83: 507-14
31. Tolins M, Weir EK, Chesler E, et al. Maximal drug therapy is not necessarily optimal in chronic angina pectoris. J Am Coll Cardiol 1984; 3: 1051-7
32. Hjalmarson A. Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the post infarction period. Am J Cardiol 1997; 80 (9B): 35J-9J
33. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007
34. Doll R, Peto R. Mortality in relation to smoking: 20 years' observations on male British doctors. BMJ 1976; 2: 1526-2536
35. Juul-Moller S, Edvardsson N, Jahnmatz B, et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992; 340: 1421-5
36. Food and Drug Administration. Acetylsalicylic acid and the heart. JAMA 1993; 270: 2669
37. Fuster V, Dyken ML, Vokonas PS, et al. Aspirin as a therapeutic agent in cardiovascular disease. Circulation 1993; 87: 659-75
38. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. N Engl J Med 2001; 345: 494-502
39. Vaughan CJ, Gotto AM, Basson CT. The evolving role of statins in the management of artherosclerosis. J Am Coll Cardiol 2000; 35: 1-10
40. Scandinavian Sinivastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease, the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
41. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 1999; 341: 70-6
42. Rubins HB, Robins S, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-8
43. Pepine C. Rationale for ACE inhibition as and-ischemic therapy. Eur Heart J 1998; 19: G34-40
44. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53
45. Pfeffer MA, Domanski M, Verter J, et al. The continuation of the Prevention of Events With Angiotensin-Converting Enzyme Inhibition (PEACE) Trial. Am Heart J 2001; 142 (3): 375-7
46. Fox K, Henderson JR, Bertrand ME, et al. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA). Eur Heart J 1998; 19 Suppl J: J52-5
47. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 527: 669-77
48. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991; 325: 293-302
49. Pepine CJ, Cohn PF, Deedwania P, et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life: the Atenolol Silent Ischemia Study (ASIST). Circulation 1994; 90 (2): 762-8
50. King LM, Opie LH. Glucose and glycogen utilization in myocardial ischemia - changes in metabolism and consequences for the myocyte. Mol Cell Biochem 1998; 180: 3-26
51. Stanley WC, Lopaschuk GD, Hall JL, et al. Regulation of myocardial carbohydrate metabolism under normal and ischemic conditions. Cardiovasc Res 1997; 33: 243-57
52. Taegtmeyer H. Energy substrate metabolism as a target for pharmacotherapy in ischemic and reperfused heart muscle. Heart and Metabolism 1998; 1: 5-9
53. Lopaschuk GD. Optimizing cardiac energy metabolism: a new approach to treating ischemic heart disease. Eur Heart J Supplement 1999; 1 Suppl O: O32-9
54. Schwartz GG, Greyson C, Wisneski JA, et al. Inhibition of fatty acid metabolism alters myocardial high energy phosphates in vivo. Am J Physiol 1994; 267: H224-31
55. Meehan AG, Higgins AJ. Oleate plus oxfenicine improves functional recovery assessed via an intraventricular balloon, in ischemic reperfused rat hearts. Ann N Y Acad Sci 1994; 723: 343-4
56. Lopaschuk GD, Kozak R. Trimetazidine inhibits fatty acid oxidation in the heart [abstract]. J Mol Cell Cardiol 1998; 30: A112
57. McCormack JG, Barr RL, Wolff AA, et al. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation 1996; 93: 135-42
58. Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000; 86: 580-8
59. Mehrotra TN, Bassadone ET. Trimetazidine in the treatment of angina pectoris. Br J Clin Pract 1967; 21: 553-4
60. Brodbin P, O'Conner CA. Trimetazidine in the treatment of angina pectoris. Br J Clin Pract 1968; 22: 395-6
61. Sellier P. The effects of trimetazidine on ergometric parameters in exercise-induced angina: controlled multicenter double blind versus placebo study [in French]. Arch Mal Coeur Vaiss 1986; 79: 1331-6
62. Sellier P, Audouin P, Payen B, et al. Ergometric effects of a single administration of trimetazidine [in French]. Presse Med 1986; 15: 1771-4
63. Passeron J. Effectiveness of trimetazidine in stable effort angina due to chronic coronary insufficiency: a double-blind versus placebo study. Presse Med 1986; 15: 1775-8
64. Gallet M. Clinical effectiveness of trimetazidine in stable effort angina: a double-blind versus placebo-controlled study. Presse Med 1986; 15: 1779-82
65. Detry JM, Sellier P, Pennaforte S, et al. Trimetazidine: a new concept in the treatment of angina: comparison with propranolol in patients with stable angina. Br J Clin Pharmacol 1994; 37: 279-88
66. Dalla-Volta S, Maraglino G, Della-Valentina P, et al. Comparison of trimetazidine with nifedipine in effort angina: a double-blind crossover study. Cardiovasc Drugs Ther 1990; 4 Suppl. 4: 853-9
67. Levy S, Manchanda SC, Krishnaswani S. Combination treatment with trimetazidine and diltiazem in stable angina pectoris. Heart 1997; 76: 353-7
68. Michaelides AP, Vyssoulis GP, Bonoris PB. Beneficial effects of trimetazidine in men with stable angina under beta-blocker treatment. Curr Therapeut Res 1989; 46: 1179-90
69. Michalides AP, Spiropoulos K, Dimopoulos K, et al. Anti-anginal efficacy of the combination of trimetazidine-proprandolol compared with isosorbide dinitrate-propranolol in patients with stable angina. Clin Drug Invest 1997; 13: 8-14
70. Chierchia SL, Fragasso G. Protective effects of trimetazidine on ischemic myocardial dysfunction. Eur Heart J Suppl 1999; 1 Suppl O: O24-7
71. Szwed H, Sadowski Z, Elikowski W, et al. Combination treatment in stable effort angina using trimetazidine and metoprolol. Eur Heart J 2001; 22: 2267-74
72. Shlyakhto E, Almazov VVA, Nifontov EM, et al. Anti-anginal effects of trimetazidine and left ventricular function improvement in patients with stable angina pectoris. Am J Cardiovasc Drugs 2002; 2: 119-24
73. Aaker A, McCormack JG, Hirai T, et al. Effects of ranolazine on the exercise capacity of rats with chronic heart failure induced by myocardial infarction. J Cardiovasc Pharmacol 1996; 28 (3): 353-62
74. Jain D, Dasgupta P, Hughes LO, et al. Ranolazine (RS-43285): a preliminary study of a new anti-anginal agent with selective effect on ischemic myocardium. Eur J Clin Pharmacol 1990; 38 (2): 111-4
75. Cocco G, Rousseau MF, Bouvy T, et al. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem. J Cardiovasc Pharmacol 1992; 20 (1): 131-8
76. Thadani U, Ezekowitz M, Fenney L, et al. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group. Circulation 1994; 90 (2): 726-34
77. Pepine CJ, Wolff AA. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional anti-anginal agents. Am J Cardiol 1999; 84 (1): 46-50
78. Wolff AA. Monotherapy assessment of ranolazine in stable angina [abstract]. The MARISA Study Group. J Am Coll Cardiol 2000; 35 Suppl A: 408A
79. Chaitman B. A phase III, multinational, randomized, double-blind, placebo-controlled, parallel group trial of the safety and efficacy of ranolazine in angina. The CARISA Study Group. Presented at the Annual meeting of the American College of Cardiology; 2002 Mar 17-20; Atlanta (Georgia), USA
80. Shapiro W, Dibianco R, Thadani U. Comparative efficacy of 200, 300, and 400mg of bepridil for chronic, stable angina pectoris. Am J Cardiol 1985; 55: 36C-42C